In Massachusetts, Audax Medical, Inc. has a worldwide license from Northeastern University for new nanotechnology of a self-assembling arginine-rich peptide to add to its current tissue regeneration platform. They plan to use this new nanotech for their medical applications and tissue regeneration. The newly developed nanostructures have antimicrobial properties, but unlike antibiotics which go after specific cellular activity, the nanoparticles aim specifically for the microorganisms’ cytoplasmic membrane which limits the inflammation and infection in surrounding tissue. Mark Johanson, Audax’s CEO, told PR Newswire, “We are excited to be collaborating with Northeastern’s team of world-class researchers. This technology fits perfectly with our company’s core biologics platform, while expanding potential clinical opportunities in the growing Wound Care and Anti-Infection markets.”
Latest article
Bioplastic straws an unlikely savior for coral
In Florida, researchers have developed a novel solution to keeping young, vulnerable coral from being eaten by predatory fish: protective cages made from bioplastic...
Canadian rapper Drake photographed sporting biobased EVA slip ons from Kane
In Canada, “Hotline Bling” rapper Drake has been seen sporting pink biobased slip-on shoes designed by Kane.
Founded in 2020 by former Maverik Lacrosse CEO...
Sorry parents, fruit waste glitter is still a pain to clean up
In the United Kingdom, scientists at Cambridge University have developed biodegradable glitter made from nanocrystals of cellulose extracted from fruit waste.
The sustainable sparkle solution...